{"disease":{"id":"primary-central-nervous-system-lymphoma","name":"primary central nervous system lymphoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":4},"drugs":{"marketed":[{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic primary central nervous system lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tisagenlecleucel","indication_name":"primary central nervous system lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06830421","title":"Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"University Hospital Freiburg","has_results":false},{"nct_id":"NCT01421524","title":"Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":271,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04792489","title":"DALY II USA/ MB-CART2019.1 for DLBCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":248,"lead_sponsor_name":"Miltenyi Biomedicine GmbH","has_results":false},{"nct_id":"NCT07185373","title":"Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":215,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT05334238","title":"Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":174,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06115824","title":"New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen","phase":"","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04129710","title":"A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04947319","title":"Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":119,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07350850","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04186520","title":"CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT02315326","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT07007611","title":"The Role of Surgical Resection AND Stereotactic Radiosurgery in Primary Central Nervous System -Diffuse Large B Cell Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"jiahong Deng","has_results":false},{"nct_id":"NCT03495960","title":"Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"International Extranodal Lymphoma Study Group (IELSG)","has_results":false},{"nct_id":"NCT06439420","title":"CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false},{"nct_id":"NCT02203526","title":"Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04870944","title":"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":63,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03582254","title":"Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years","phase":"NA","overall_status":"UNKNOWN","enrollment_count":62,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06755619","title":"CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Nordic Lymphoma Group","has_results":false},{"nct_id":"NCT03038672","title":"Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05390749","title":"Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07410520","title":"PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06832267","title":"Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL","phase":"NA","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT07523737","title":"Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT04457869","title":"A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":43,"lead_sponsor_name":"Shandong New Time Pharmaceutical Co., LTD","has_results":false},{"nct_id":"NCT06946407","title":"Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"FengYan Jin","has_results":false},{"nct_id":"NCT07198087","title":"A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04831658","title":"A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Mingzhi Zhang","has_results":false},{"nct_id":"NCT07074470","title":"Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06556199","title":"A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04421560","title":"Pembrolizumab, Ibrutinib and Rituximab in PCNSL","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05549284","title":"Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Affiliated Hospital to Academy of Military Medical Sciences","has_results":false},{"nct_id":"NCT01588015","title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05351593","title":"Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"James Rubenstein","has_results":false},{"nct_id":"NCT07014943","title":"High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":34,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT04514393","title":"Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":33,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT04899427","title":"Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06646211","title":"High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04066920","title":"IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Deok-Hwan Yang","has_results":false},{"nct_id":"NCT07198464","title":"Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Zhengzhou University","has_results":false},{"nct_id":"NCT04737889","title":"Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT03323034","title":"Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT06445257","title":"A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Huai'an First People's Hospital","has_results":false},{"nct_id":"NCT01722305","title":"Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06175000","title":"Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Providence Health & Services","has_results":false},{"nct_id":"NCT05600660","title":"Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04906096","title":"Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Lakshmi Nayak, MD","has_results":false},{"nct_id":"NCT03703167","title":"Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02655744","title":"Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute","phase":"","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}